{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:50:56Z","timestamp":1761897056836},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1038\/s41409-019-0574-5","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T11:02:36Z","timestamp":1559300556000},"page":"1908-1919","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells"],"prefix":"10.1038","volume":"54","author":[{"given":"Antonio","family":"Olry de Labry Lima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Gimeno-Ballester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"R\u00edos Tamayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Matas Hoces","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esmeralda","family":"R\u00edos S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Garc\u00eda Moch\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio Jes\u00fas","family":"Alegre-del Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"key":"574_CR1","unstructured":"Agencia espa\u00f1ola de medicamentos y productos sanitarios. Informe de Posicionamiento Terap\u00e9utico de lenalidomida nuevo diagn\u00f3stico en pacientes no candidatos a trasplante. 2015. p . 1\u20139. \nhttps:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-lenalidomida-Revlimid.pdf\n\n. Accessed 10 Mar 2018."},{"key":"574_CR2","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374\u2013403. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2012.12.027","journal-title":"Eur J Cancer"},{"key":"574_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/ijc.27711","volume":"132","author":"F Bray","year":"2013","unstructured":"Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133\u201345. \nhttps:\/\/doi.org\/10.1002\/ijc.27711","journal-title":"Int J Cancer"},{"key":"574_CR4","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770\u201381. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1114083","journal-title":"N Engl J Med"},{"key":"574_CR5","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","volume":"4","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4:e431\u2013e442. \nhttps:\/\/doi.org\/10.1016\/S2352-3026(17)30140-0","journal-title":"Lancet Haematol"},{"key":"574_CR6","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782\u201391. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1114138","journal-title":"N Engl J Med"},{"key":"574_CR7","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017;31:1915\u201321. \nhttps:\/\/doi.org\/10.1038\/leu.2016.380","journal-title":"Leukemia"},{"key":"574_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","volume":"18","author":"A Teitelbaum","year":"2013","unstructured":"Teitelbaum A, Ba-Mancini A, Huang H, Henk HJ. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist. 2013;18:37\u201345. \nhttps:\/\/doi.org\/10.1634\/theoncologist.2012-0113","journal-title":"Oncologist"},{"key":"574_CR9","unstructured":"Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review report by the decision support unit. 2017. p . 1\u201372. \nhttp:\/\/scharr.dept.shef.ac.uk\/nicedsu\/wp-content\/uploads\/sites\/7\/2017\/06\/Partitioned-Survival-Analysis-final-report.pdf"},{"key":"574_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/00019053-200725010-00002","volume":"25","author":"RL Fleurence","year":"2007","unstructured":"Fleurence RL, Hollenbeak CS. Rates and Probabilities in Economic Modelling. Pharmacoeconomics. 2007;25:3\u20136. \nhttps:\/\/doi.org\/10.2165\/00019053-200725010-00002","journal-title":"Pharmacoeconomics"},{"key":"574_CR11","unstructured":"European Medicines Agency. Assessment report Revlimid. 2017;44. \nhttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/revlimid"},{"key":"574_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Method. 2012;12:9. \nhttps:\/\/doi.org\/10.1186\/1471-2288-12-9\n\n.","journal-title":"BMC Med Res Method"},{"key":"574_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0272989X16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Mackay DF, Briggs AH. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling. Med Decis Mak. 2017;37:427\u201339.","journal-title":"Med Decis Mak"},{"key":"574_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-12-35","volume":"12","author":"I Proskorovsky","year":"2014","unstructured":"Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J, et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes. 2014;12:1\u20139. \nhttps:\/\/doi.org\/10.1186\/1477-7525-12-35","journal-title":"Health Qual Life Outcomes"},{"key":"574_CR15","unstructured":"Agencia espa\u00f1ola de medicamentos y productos sanitarios. Informe de Posicionamiento Terap\u00e9utico de daratumumab reca\u00edda y refractario. 2017. p. 1\u20136. \nhttps:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-daratumumab-Darzalex-mieloma-multiple.pdf\n\n. Accessed 17 Feb 2018."},{"key":"574_CR16","unstructured":"European Medicines Agency. EPAR Darzalex, INN-daratumumab. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/004077\/WC500228981.pdf\n\n. Accessed 17 Feb 2018."},{"key":"574_CR17","unstructured":"European Medicines Agency. CHMP-Kyprolis (carfilzomib)-EMA\/517040\/2016. \nhttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003790\/human_med_001932.jsp&mid=WC0b01ac058001d124\n\n. Accessed 19 Feb 2018."},{"key":"574_CR18","unstructured":"Agencia espa\u00f1ola de medicamentos y productos sanitarios. Informe de Posicionamiento Terap\u00e9utico de de Pomalidomida (Imnovid\u00ae). 2015. p. 1\u20135. \nhttps:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-pomalidomida-imnovid.pdf\n\n. Accessed 17 Feb 2018."},{"key":"574_CR19","unstructured":"Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. Bolet\u00edn Oficial del estado 2013;126:45070\u2013128."},{"key":"574_CR20","first-page":"e013","volume":"23","author":"R LeBlanc","year":"2016","unstructured":"LeBlanc R, Tay J, Hollmann S, Shustik J. A Canadian cost analysis comparing the use of bortezomib or lenalidomide as maintenance therapies in multiple myeloma patients eligible for autologous stem cell transplant. J Popul Ther Clin Pharm. 2016;23:e013\u2013113.","journal-title":"J Popul Ther Clin Pharm"},{"key":"574_CR21","unstructured":"ORDEN de 14 de octubre de 2005, por la que se fijan los precios p\u00fablicos de los servicios sanitarios prestados por Centros dependientes del Sistema Sanitario P\u00fablico de Andaluc\u00eda. \nhttp:\/\/juntadeandalucia.es\/boja\/2005\/210\/28\n\n. Accessed 2 May 2018."},{"key":"574_CR22","unstructured":"Orden de 8 de noviembre de 2016, por la que se modifica la Orden de 14 de octubre de 2005, por la que se fijan los precios p\u00fablicos de los servicios sanitarios prestados por centros dependientes del Sistema Sanitario P\u00fablico de Andaluc\u00eda. 2016. p. 42\u201361. \nhttp:\/\/juntadeandalucia.es\/boja\/2016\/218\/1\n\n. Accessed 3 May 2018."},{"key":"574_CR23","unstructured":"Colecci\u00f3n Consejo BOT Plus, Consejo General de Colegios Oficiales de Farmac\u00e9uticos. \nhttps:\/\/botplusweb.portalfarma.com\/\n\n. Accessed 10 Feb 2018."},{"key":"574_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","volume":"24","author":"J L\u00f3pez Bastida","year":"2010","unstructured":"L\u00f3pez Bastida J, Oliva J, Anto\u00f1anzas F. Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias. Gac Sanit. 2010;24:154\u201370. \nhttps:\/\/doi.org\/10.1016\/j.gaceta.2009.07.011","journal-title":"Gac Sanit"},{"key":"574_CR25","unstructured":"Agencia espa\u00f1ola de medicamentos y productos sanitarios. Informe de Posicionamiento Terap\u00e9utico de de Revlimid en mantenimiento. \nhttps:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-lenalidomida-Revlimid-mantenimiento-mieloma-multiple.pdf\n\n. Accessed 17 Feb 2018."},{"key":"574_CR26","doi-asserted-by":"publisher","first-page":"831","DOI":"10.18553\/jmcp.2017.23.8.831","volume":"23","author":"Y Chen","year":"2017","unstructured":"Chen Y, Lairson DR, Chan W, Huo J, Du XL. Cost-effectiveness of novel agents in medicare patients with multiple myeloma: findings from a U.S. payer\u2019s perspective. J Manag Care Spec Pharm. 2017;23:831\u201343. \nhttps:\/\/doi.org\/10.18553\/jmcp.2017.23.8.831","journal-title":"J Manag Care Spec Pharm"},{"key":"574_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/13696998.2017.1421546","volume":"21","author":"S Gonzalez-McQuire","year":"2018","unstructured":"Gonzalez-McQuire S, Yong K, Leleu H, Mennini FS, Flinois A, Gazzola C, et al. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. J Med Econ. 2018;21:450\u201367.","journal-title":"J Med Econ"},{"key":"574_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/jcpt.12384","volume":"41","author":"PM Aguiar","year":"2016","unstructured":"Aguiar PM, Lima TM, Storpirtis S. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality? J Clin Pharm Ther. 2016;41:189\u201397. \nhttps:\/\/doi.org\/10.1111\/jcpt.12384","journal-title":"J Clin Pharm Ther"},{"key":"574_CR29","first-page":"3405","volume":"130","author":"G Jackson","year":"2017","unstructured":"Jackson G, Dutton R, Zamagni E, Hughes R, Dhanasiri S. Lenalidomide maintenance therapy post-autologous stem cell transplant: a healthcare cost-impact analysis in Europe. Blood. 2017;130:3405.","journal-title":"Blood"},{"issue":"Suppl 15","key":"574_CR30","doi-asserted-by":"publisher","first-page":"e19509","DOI":"10.1200\/JCO.2017.35.15_suppl.e19509","volume":"35","author":"J Xie","year":"2017","unstructured":"Xie J, Parikh K, Chen C, Yang C, Farruth A, Cockrum P, et al. Impact of FDA approval of lenalidomide maintenance therapy in the first-line treatment of multiple myeloma after autologous stem cell transplant on total healthcare costs. J Clin Oncol. 2017;35 Suppl 15:e19509\u2013e19509.","journal-title":"J Clin Oncol"},{"key":"574_CR31","first-page":"3073","volume":"7","author":"M Gao","year":"2014","unstructured":"Gao M, Gao L, Yang G, Tao Y, Tompkins VS, Wu X, et al. Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials. Int J Clin Exp Pathol. 2014;7:3073\u201380.","journal-title":"Int J Clin Exp Pathol"},{"key":"574_CR32","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s40265-017-0795-0","volume":"77","author":"YY Syed","year":"2017","unstructured":"Syed YY. Lenalidomide: a review in newly diagnosed multiple myeloma as maintenance therapy after ASCT. Drugs. 2017;77:1473\u201380. \nhttps:\/\/doi.org\/10.1007\/s40265-017-0795-0","journal-title":"Drugs"},{"key":"574_CR33","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1634\/theoncologist.2017-0440","volume":"23","author":"ED Pulte","year":"2018","unstructured":"Pulte ED, Dmytrijuk A, Nie L, Goldberg KB, McKee AE, Farrell AT, et al. FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma. Oncologist. 2018;23:734\u20139. \nhttps:\/\/doi.org\/10.1634\/theoncologist.2017-0440","journal-title":"Oncologist"},{"key":"574_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/ejh.12961","volume":"99","author":"F Al-Ani","year":"2017","unstructured":"Al-Ani F, Louzada M. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: a systematic review. Eur J Haematol. 2017;99:479\u201388. \nhttps:\/\/doi.org\/10.1111\/ejh.12961","journal-title":"Eur J Haematol"},{"key":"574_CR35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0272989X16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Mackay DF, Briggs AH. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling. Med Decis Mak. 2017;37:427\u201339. \nhttps:\/\/doi.org\/10.1177\/0272989X16670617","journal-title":"Med Decis Mak"},{"key":"574_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18090","volume":"18","author":"L Longworth","year":"2014","unstructured":"Longworth L, Yang Y, Young T, Mulhern B, Hern\u00e1ndez Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18:1\u2013224. \nhttps:\/\/doi.org\/10.3310\/hta18090","journal-title":"Health Technol Assess"},{"key":"574_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1477-7525-9-106","volume":"9","author":"P Teckle","year":"2011","unstructured":"Teckle P, Peacock S, McTaggart-Cowan H, van der Hoek K, Chia S, Melosky B, et al. The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. Health Qual Life Outcomes. 2011;9:106. \nhttps:\/\/doi.org\/10.1186\/1477-7525-9-106","journal-title":"Health Qual Life Outcomes"},{"key":"574_CR38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10198-010-0233-7","volume":"11","author":"R Crott","year":"2010","unstructured":"Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ. 2010;11:427\u201334. \nhttps:\/\/doi.org\/10.1007\/s10198-010-0233-7","journal-title":"Eur J Health Econ"},{"issue":"4","key":"574_CR39","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/pst.1853","volume":"17","author":"Samer A. Kharroubi","year":"2018","unstructured":"Kharroubi SA, Edlin R, Meads D, McCabe C. Bayesian statistical models to estimate EQ-5D utility scores from EORTC QLQ data in myeloma. Pharm Stat. 2018;1\u201314. \nhttps:\/\/doi.org\/10.1002\/pst.1853\n\n.","journal-title":"Pharmaceutical Statistics"},{"key":"574_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2147\/CEOR.S93280","volume":"7","author":"L Oddershede","year":"2015","unstructured":"Oddershede L, Petersen KD. Adjustment of foreign EQ-5D-3L utilities can increase their transferability. Clin Outcomes Res. 2015;7:629\u201336. \nhttps:\/\/doi.org\/10.2147\/CEOR.S93280","journal-title":"Clin Outcomes Res"},{"issue":"1","key":"574_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12185-018-2543-y","volume":"109","author":"Shin-ichi Fuchida","year":"2018","unstructured":"Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, et al. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma. Int J Hematol. 2018. \nhttps:\/\/doi.org\/10.1007\/s12185-018-2543-y\n\n.","journal-title":"International Journal of Hematology"},{"key":"574_CR42","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","volume":"99","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99:3163\u20138.","journal-title":"Blood"},{"key":"574_CR43","unstructured":"Agencia espa\u00f1ola de medicamentos y productos sanitarios.Informe de Posicionamiento Terap\u00e9utico de lenalidomida (Revlimid\u00ae) en mantenimiento en mieloma m\u00faltiple. \nhttps:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-lenalidomida-Revlimid-mantenimiento-mieloma-multiple.pdf\n\n. Accessed 23 May 2018."},{"key":"574_CR44","first-page":"1","volume":"27","author":"L Vallejo\u2010Torres","year":"2017","unstructured":"Vallejo\u2010Torres L, Garc\u00eda\u2010Lorenzo B, Serrano\u2010Aguilar P. Estimating a cost\u2010effectiveness threshold for the Spanish NHS. Health Econ. 2017;27:1\u201316.","journal-title":"Health Econ"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0574-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0574-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0574-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:52Z","timestamp":1684617292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0574-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["574"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0574-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]},"assertion":[{"value":"20 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest relating to the subject matter that may affect the design, analysis, or presentation of results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}